Table 1.
Clinical trials of lipid-based–mRNA vaccines (https://clinicaltrials.gov/, accessed on 13 February 2023) [125].
| Clinical Trial No. | Phase | Name | Route of Administration | Diseases | Antigens |
|---|---|---|---|---|---|
| NCT03076385 | I | mRNA-1440 | IM | Influenza H10N8 | Hemagglutinin |
| NCT03345043 | I | mRNA-1851 | IM | Influenza H7N9 | Hemagglutinin |
| NCT04064905 | I | mRNA-1893 | IM | Zika virus | Pre-membrane and envelope glycoproteins |
| NCT04528719 | I | mRNA-1345 | IM | Respiratory syncytial virus | F glycoprotein |
| NCT03392389 | I | mRNA-1653 | IM | Metapneumovirus and parainfluenza virus type 3 (MPV/PIV3) | MPV and PIV3 F glycoproteins |
| NCT04232280 | I | mRNA-1647 | IM | Cytomegalovirus | Pentameric complex and B glycoprotein |
| NCT03325075 | II | mRNA-1388 | IM | Chikungunya virus | Chikungunya virus antigens |
| NCT03713086 | I | CV7202 | IM | Rabies virus | G glycoprotein |
| NCT03948763 | I | mRNA-5671/V941 | IM | Non-small-cell lung cancer/colorectal cancer/pancreatic adenocarcinoma | KRAS antigens |
| NCT03897881 | I | mRNA-4157 | IM | Melanoma | Personalized neoantigens |
| NCT03480152 | I/II | mRNA-4650 | IM | Gastrointestinal cancer | Personalized neoantigens |
| NCT02410733 | I | FixVac | IV | Melanoma | NY-ESO-1/tyrosinase/MAGE-A3/TPTE antigen |
| NCT02316457 | I | TNBC- MERIT | IV | Triple- negative breast cancer | Personalized neoantigens |
| NCT03418480 | I | HARE-40 | ID | HPV-positive cancers | HPV oncoproteins E6 and E7 |
| NCT03815058 | II | RO7198457 | IV | Melanoma | Personalized neoantigens |
| NCT04163094 | I | W_ova1 | IV | Ovarian cancer | Ovarian cancer antigens |
| NCT03739931 | I | mRNA Vaccine | Intra-tumoral (IT) | Solid tumors and Lymphomas | Ligand for OX40 receptor associated with tumor necrosis factor receptor superfamily (OX40L) |
| NCT03323398 | I/II | mRNA Vaccine | IT | Solid tumors, lymphomas and ovarian cancer | OX40L |
| NCT04283461 | I | mRNA Vaccine | IM | COVID-19 | S protein |
| NCT03767270 | I | mRNA Vaccine | IV | Ornithine Transcarbamylase (OTC) deficiency | Ornithine transcarbamylase (OTC) |
| NCT04064905 | I | mRNA Vaccine | IM | Zika | pre-membrane protein (prM) and envelope protein (E) |
| NCT03382405 | I | mRNA-1647l, mRNA-1443 | IM | CMV infection | Pentamer and T-cell antigen |
| NCT03713086 | I | unmodified mRNA vaccine: CV7202 | IM | Rabies | Rabies virus glycoprotein (RABV-G)-mRNA vaccine |
| NCT03014089 | I | mRNA-1325 | IM | Zika | Viral antigens |